Navigation Links
Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US
Date:12/16/2008

SEATTLE, Dec. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.(CTI) (Nasdaq and MTA: CTIC) announced today they have closed the transaction with Spectrum Pharmaceuticals, Inc. to form a 50/50 owned joint venture, RIT Oncology LLC (LLC), to commercialize and develop Zevalin(R) ([90Y]-ibritumomab tiuxetan) in the United States. In connection with the closing, Cell Therapeutics received an initial payment of $7.5 million and will receive an additional $7.5 million in early January. The Company may earn an additional $15 million in product sales milestone payments upon achievement of certain revenue targets.

"RIT Oncology is the first business venture focused on the advancement of radioimmunotherapy (RIT) in the treatment of lymphoma which provides significant resources to help accomplish that mission," said James A. Bianco, M.D., CEO of Cell Therapeutics, Inc. "RIT like Zevalin has been underutilized since its introduction in 2002. With the potential for a first-line indication for consolidation of remission in patients with follicular non-Hodgkin's lymphoma, we will be uniquely positioned to maximize physician and patient access with this potentially valuable treatment option."

Zevalin, a radioimmunotherapeutic, has been exclusively marketed by CTI in the United States since December, 2007 and will now be marketed jointly by CTI and Spectrum through the LLC for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL), including patients who have rituximab-refractory follicular NHL. The U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, a supplemental Biologics License Application (sBLA) filed by CTI for use of Zevalin as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. A Prescription Drug User Fee Act (
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R)
2. Prime Therapeutics Announces Blue Cross and Blue Shield of Montana as a Pharmacy Benefit Services Client
3. Agile Therapeutics Abstracts on Lead Product, AG200-15 Accepted by ACOG
4. Cell Therapeutics, Inc. to Offer to Repurchase up to $124 Million of Its Notes
5. Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints
6. Transition Therapeutics Announces Dates for Upcoming Corporate Events
7. Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer
8. Precision Therapeutics Secures $43 Million in Venture Capital Funding
9. Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results
10. Hyperion Therapeutics Completes Phase 2 Data Analysis and Schedules End of Phase 2 Meeting With FDA for HPN-100 in the Chronic Treatment of Urea Cycle Disorders
11. Transition Therapeutics Announces First Quarter Fiscal 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... NJ (PRWEB) August 30, 2014 The ... facilities in New Jersey and even in the U.S. ... that takes inches off of patients’ waists with deep-tissue ... cells in small sections, Vanquish is more inclusive to ... Patients lay comfortably under panels about one inch ...
(Date:8/30/2014)... 30, 2014 After offering hyperbaric ... for the past several years, Dr. Roy Schmidt ... have announced a scholarship program for veterans who ... a meeting held this summer to discuss veterans’ ... reporters have shed light on the large number ...
(Date:8/30/2014)... Calif. (PRWEB) August 30, 2014 Insomnia causes ... helps listeners understand how they unknowingly developed insomnia and the ... restful nights during. Tune in to the show at ... The show airs live on August 30, and will be ... information on programming, go to DrCarolFrancisTalkRadio.com. , "Insomnia ...
(Date:8/30/2014)... "My wife suffered neck, back and spine injuries ... of two inventors from Bethel, Alaska. "The whiplash contributed ... area. She tried other pillows to little avail. The ... comfort and providing extra sleep." , They created a ... head, neck and back comfortably. This enables the user ...
(Date:8/30/2014)... Bringing forth the great opportunities, India's ... Labor Day discount on all SEO services. While working ... services related to internet marketing. Their dedicated team of ... do have a deep understanding for their specialization. This ... and since the inception, they have worked with over ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, The Plastic Surgery Group 2Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Sleepless Nights, Exhausting Days, Mental Fog – Relief for Insomnia With Clinical Psychologist Dr. Carol Francis 2Health News:Profit By Search Announces Labor Day Discount on SEO Services 2
... is regulated by a peptide known as C3a, which directly affects ... for the migration of new nerve cells through the brain tissue, ... Stem Cells . Although the research has been carried ... new medicine for human beings, which could be given to patients ...
... of Agriculture (USDA) has awarded a two-year, $908,280 grant ... complete sequencing the genome of the domesticated turkey, Meleagris ... Genome Sequencing Consortium to complete the genome sequencing using ... genes and functions in the final genome sequence by ...
... NEW YORK, Nov. 23 Ann Taylor Stores Corp. announced ... partner for the 6th annual Thanks and Giving campaign, a ... Hospital. This year marks the third year that Ann Taylor, ... the campaign where we offer our shoppers an opportunity to ...
... , NEW ORLEANS, Nov. 23 Thanksgiving weekend marks ... the Classic represents the sportsmanship and pride of two schools but it ... Orleans and those in attendance. , For the crew of the new ... some down time before they work to test and launch a brand ...
... bacterial proteins that are toxic to certain insects, yet ... 200 million hectares worldwide. The popularity of these Bt ... comes from their ability to kill some major pests, ... by reducing insecticide sprays. However, since insects can ...
... it take longer to get sick, study finds , MONDAY, ... variation appears to play a major role in slowing disease ... variation appear to take years longer to develop AIDS and ... on factors that vary across individuals that make a person ...
Cached Medicine News:Health News:Turkey Genome Sequencing Consortium awarded $0.9 million from USDA 2Health News:Ann Taylor Stores Corp. Returns To St. Jude Children's Research Hospital's Thanks and Giving Campaign(R) For The Third Year 2Health News:Nothing Is Like Being There 2Health News:Insect resistance to Bt crops can be predicted, monitored and managed 2Health News:Genetic Variant Slows AIDS Progression 2
(Date:8/29/2014)... 29, 2014 Research and Markets ... Development Trend Forecast of Pharmaceutical Equipment Market in China, ... Research and Development Trend Forecast of Pharmaceutical Equipment Market ... China,s pharmaceutical equipment industry in ... competition landscape, and business performance of domestic major enterprises, ...
(Date:8/29/2014)... , August 29, 2014 ... Market by Product & Services (Equipment, Reagent, Primer, ... Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, ... MarketsandMarkets, the global Oligonucleotide Synthesis Market is expected ... Million in 2014, growing at a CAGR of ...
(Date:8/29/2014)... /PRNewswire-iReach/ -- ChemImage will present a workshop focused on ... Forensic Science Society,s 22 nd International Symposium ... Australia .  Forensic Scientists will be in ... imaging can bring to examination procedures. ... Product Development at ChemImage, will host a workshop ...
Breaking Medicine Technology:Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
... that results from the REMEDEE study ( R andomized ... inal sirolimus coat ED bio- E ... Therapy Stent is non-inferior to the TAXUS® Liberte® paclitaxel-eluting stent, with ... results were presented by Michael Haude, M.D., director of Medical Clinic ...
... University Hospitals (UH) Case Medical Center, Case Western ... today the initiation of a novel Phase I clinical ... hematopoietic stem cells (HSCs) from the dose limiting toxicity ... Americans are diagnosed with glioblastoma every year and only ...
Cached Medicine Technology:REMEDEE Study Meets Primary Endpoint: OrbusNeich's Combo™ Dual Therapy Stent Is Non-Inferior to DES 2REMEDEE Study Meets Primary Endpoint: OrbusNeich's Combo™ Dual Therapy Stent Is Non-Inferior to DES 3REMEDEE Study Meets Primary Endpoint: OrbusNeich's Combo™ Dual Therapy Stent Is Non-Inferior to DES 4Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer 2Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer 3Lentigen and UH Case Medical Center Initiate Phase I Trial Using Gene Therapy and Bone Marrow Stem Cells in the Treatment of Brain Cancer 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... System is a panel mounted system that offers ... needs of the heath care professional using the ... available with a dual action lever that allows ... to an IV pole. Similarly, it features ...
Medicine Products: